Nilotinib, Dasatinib Offer Similar Outcomes in CML Patients

A propensity score –matched comparison of two phase II trials found that dasatinib and nilotinib offer similar responses and outcomes as first-line therapy for patients with chronic-phase CML.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Tags: Chronic Myeloid Leukemia Hematologic Malignancies & Lymphoma News Source Type: news

Related Links:

Publication date: Available online 6 March 2020Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Shuvadeep Ganguly, Deepam Pushpam, Agrima Mian, Anita Chopra, Ritu Gupta, Sameer Bakhshi
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
AbstractBackgroundSALL4 is a zinc finger transcription factor that exerts its physiological role during embryo-fetal development. Analyses of SALL4 expression have shown its oncogenic role in precursor B-cell lymphoblastic lymphoma, acute and chronic myeloid leukemia, gastrointestinal, breast, and lung cancers. The aim of this study was to determine the immunohistochemical profile of SALL4 in pediatric yolk sac tumors (YSTs).Methods and resultsImmunohistochemistry detection of SALL4 was performed in 22 cases of pediatric YSTs and 10 mature teratomas. The percentage of tumor cells stained was scored as 0, 1+  (1&ndas...
Source: Pediatric Surgery International - Category: Surgery Source Type: research
CONCLUSION: The 3-(acridin-9-ylmethyl)-5-((10-chloroanthracen-9-yl)methylene)thiazolidine-2,4-dione (LPSF/AA-62) presented the most promising results, showing anti-tumor activity in 5 of the 6 cell types tested, especially inhibiting the formation of colonies of prostate tumor cells (DU-145). PMID: 32189590 [PubMed - as supplied by publisher]
Source: Combinatorial Chemistry and High Throughput Screening - Category: Chemistry Authors: Tags: Comb Chem High Throughput Screen Source Type: research
Publication date: Available online 6 March 2020Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Shuvadeep Ganguly, Deepam Pushpam, Agrima Mian, Anita Chopra, Ritu Gupta, Sameer Bakhshi
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Chronic myeloid leukemia is a rare malignancy in children, predominantly seen in adolescence, with relatively aggressive disease biology compared with adults. Despite practical constraints like poor treatment adherence and financial unaffordability of second-generation tyrosine kinase inhibitors, as major challenges in management, a 5-year overall survival rate and an event-free survival of 92% and 64%, respectively, were achieved in our study cohort with imatinib as frontline therapy. Dose augmentation of imatinib is a reasonable option in those with a suboptimal response.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research
Chronic myeloid leukaemia is a rare malignancy in children predominantly seen in adolescence with relatively aggressive disease biology compared to adults. Despite practical constraints like poor treatment adherence and financial unaffordability of second-generation tyrosine kinase inhibitors as major challenges in management, 5-year OS and EFS of 92% and 64% respectively were achieved in our study cohort with imatinib as frontline therapy. Dose augmentation of imatinib is a reasonable option in those with suboptimal response.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research
T cell cancer neoantigens are created from peptides derived from cancer-specific aberrant proteins, such as mutated and fusion proteins, presented in complex with human leukocyte antigens on the cancer cell surface. Because expression of the aberrant target protein is exclusive to malignant cells, immunotherapy directed against neoantigens should avoid “on-target, off-tumor” toxicity. The efficacy of neoantigen vaccines in melanoma and glioblastoma and of adoptive transfer of neoantigen-specific T cells in epithelial tumors indicates that neoantigens are valid therapeutic targets. Improvements in sequencing tec...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
Publication date: Available online 12 February 2020Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): O.V. Lazareva, A.G. Turkina, E.Yu Chelysheva, A.A. Kulikovsky, M.A. Galayko, O.M. Senderova, V.M. Pepeliaeva, S.V. Meresiy, A.S. Luchinin, G.I. Milutina, L.V. Gavrilova, L.B. Avdeeva, E.B. Dasheeva, O.Yu Vinogradova, H.L. Julhakyan, S.M. KulikovIntroductionRussia took part in the multicenter population-based Study (Europe) and included 6.8% adult patients (pts) with newly diagnosed chronic myeloid leukemia (CML) (Hoffman V et al. 2016).ObjectiveTo analyze the mortality in the Russian cohort of patients (pts) with new...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
The objective of this study was to analyze the mortality in the Russian cohort of patients with newly diagnosed CML in the EUTOS PBS observational study.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Current Trial Report Source Type: research
Publication date: Available online 27 January 2020Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Xuelin Dou, Yazhen Qin, Yueyun Lai, Hongxia Shi, Xiaojun Huang, Qian JiangAbstractIntroductionTo compare the efficacy and safety of generic and branded imatinib in adults with newly diagnosed chronic myeloid leukaemia in the chronic phase (CML-CP), we retrospectively reviewed data from patients CML-CP receiving generic or branded imatinib.Patients and MethodsA propensity score matching (PSM) study was performed. Cox regression model was used to identify factors associated with responses and outcomes.Results442 adults ...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
More News: Cancer & Oncology | Chronic Leukemia | Chronic Myeloid Leukaemia | Hematology | Leukemia | Lymphoma | Nilotinib | Tasigna